PRESS RELEASE published on 03/19/2026 at 06:58, 4 months 22 days ago DocMorris achieves 2025 targets – focus on profitability, growth and expansion of digital health platform DocMorris AG achieves 2025 targets with focus on profitability, growth, and digital health platform expansion. Partnership with Google boosts AI strategy. Ludwigshafen site closure for efficiency Profitability Growth DocMorris AG 2025 Targets Digital Health Platform
BRIEF published on 03/03/2026 at 07:05, 5 months 7 days ago DocMorris AG annonce des changements au sein de son conseil d'administration Stratégie D'entreprise Assemblée Générale Annuelle DocMorris AG Changements Au Conseil D'administration Nouvelles Nominations
BRIEF published on 03/03/2026 at 07:05, 5 months 7 days ago DocMorris AG Announces Changes to Its Board of Directors Annual General Meeting New Appointments Board Changes Corporate Strategy DocMorris AG
PRESS RELEASE published on 03/03/2026 at 07:00, 5 months 7 days ago DocMorris AG announces changes to its Board of Directors DocMorris AG announces changes to its Board of Directors, with Prof. Stefan Feuerstein, Dr Christian Mielsch, and Rongrong Hu not standing for re-election, proposing the election of new members at the upcoming Annual General Meeting Board Of Directors Annual General Meeting Personnel Changes DocMorris AG New Members
BRIEF published on 02/02/2026 at 17:50, 6 months 7 days ago DocMorris Announces Early Redemption of 6.875% Convertible Bonds Convertible Bonds Finance Early Redemption DocMorris Bond Conversion
BRIEF published on 02/02/2026 at 17:50, 6 months 7 days ago DocMorris annonce le remboursement anticipé d'obligations convertibles à 6,875 % Obligations Convertibles Finance DocMorris Conversion D'obligations Rachat Anticipé
PRESS RELEASE published on 02/02/2026 at 17:45, 6 months 7 days ago Early redemption of the 6.875% Convertible Bonds due 2026 DocMorris Finance B.V. exercises early redemption option for 6.875% Convertible Bonds due 2026, to be redeemed at nominal value plus accrued interest. Bonds may be converted into DocMorris AG shares Shares Convertible Bonds Early Redemption Redeem DocMorris
BRIEF published on 01/26/2026 at 18:35, 6 months 14 days ago DocMorris rachète des obligations convertibles arrivant à échéance en 2026 Obligations Convertibles Gestion Financière DocMorris AG Échéance 2026 Stratégie De Rachat
BRIEF published on 01/26/2026 at 18:35, 6 months 14 days ago DocMorris Repurchases Convertible Bonds Maturing in 2026 Financial Management Convertible Bonds DocMorris AG 2026 Maturity Repurchase Strategy
PRESS RELEASE published on 01/26/2026 at 18:30, 6 months 14 days ago DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million DocMorris repurchases CHF 14.4 million convertible bonds maturing in 2026, reducing total outstanding amount Convertible Bonds Repurchase DocMorris 2026 CHF 14.4 Million
Published on 08/10/2026 at 08:00, 2 hours 9 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 9 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 10 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 09:50, 19 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 8 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 8 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 9 minutes ago Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
Published on 08/10/2026 at 09:22, 46 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 46 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 9 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 9 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité